1-17 of 17
Feng Gao
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (22): 4698.
https://doi.org/10.1158/1078-0432.CCR-23-2993
Published: 14 November 2023
View article titled, Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study
Open the PDF for Correction: Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: a Phase I Dose Escalation and Expansion Study in another window
Journal Articles

Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study

Andrea Wang-Gillam, Kian-Huat Lim, Robert McWilliams, Rama Suresh, Albert C. Lockhart, Amberly Brown, Marcus Breden, Jad I. Belle, John Herndon, Savannah J. Bogner, Katrina Pedersen, Benjamin Tan, Nicholas Boice, Abhi Acharya, Mina Abdiannia, Feng Gao, Harry H. Yoon, Mojun Zhu, Nikolaos A. Trikalinos, Lee Ratner, Olivia Aranha, William G. Hawkins, Brett H. Herzog, David G. DeNardo
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (24): 5254–5262.
https://doi.org/10.1158/1078-0432.CCR-22-0308
Published: 15 December 2022
View article titled, Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study
Open the PDF for Defactinib, Pembrolizumab, and Gemcitabine in Patients with Advanced Treatment Refractory Pancreatic Cancer: A Phase I Dose Escalation and Expansion Study in another window
Includes: Supplementary data
Journal Articles

The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy J. Pluard, Julie R. Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason M. Jones, Nancy U. Lin, Eric P. Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Leslie Bucheit, Richard Bryce, Alshad S. Lalani, Lisa A. Carey, Matthew P. Goetz, Feng Gao, Gretchen Kimmick, Mark D. Pegram, Matthew J. Ellis, Ron Bose
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (7): 1258–1267.
https://doi.org/10.1158/1078-0432.CCR-21-3418
Published: 01 April 2022
View article titled, The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
Open the PDF for The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

OCaMIR—A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study

Raju Kandimalla, Wei Wang, Fan Yu, Nianxin Zhou, Feng Gao, Monique Spillman, Lucie Moukova, Ondrej Slaby, Bodour Salhia, Shengtao Zhou, Xin Wang, Ajay Goel
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (15): 4277–4286.
https://doi.org/10.1158/1078-0432.CCR-21-0267
Published: 01 August 2021
View article titled, OCaMIR—A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study
Open the PDF for OCaMIR—A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective Study in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma

Jennifer A. Foltz, Brian T. Hess, Veronika Bachanova, Nancy L. Bartlett, Melissa M. Berrien-Elliott, Ethan McClain, Michelle Becker-Hapak, Mark Foster, Timothy Schappe, Brad Kahl, Neha Mehta-Shah, Amanda F. Cashen, Nancy D. Marin, Kristen McDaniels, Chaz Moreno, Matthew Mosior, Feng Gao, Obi L. Griffith, Malachi Griffith, Julia A. Wagner, Narendranath Epperla, Amy D. Rock, John Lee, Allegra A. Petti, Patrick Soon-Shiong, Todd A. Fehniger
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (12): 3339–3350.
https://doi.org/10.1158/1078-0432.CCR-20-4575
Published: 15 June 2021
View article titled, Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma
Open the PDF for Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

EGFR Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma

Shaofang Wu, Feng Gao, Siyuan Zheng, Chen Zhang, Emmanuel Martinez-Ledesma, Ravesanker Ezhilarasan, Jie Ding, Xiaolong Li, Ningping Feng, Asha Multani, Erik P. Sulman, Roel G. Verhaak, John F. de Groot, Tim P. Heffernan, W.K. Alfred Yung, Dimpy Koul
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (6): 1395–1407.
https://doi.org/10.1158/1078-0432.CCR-19-2549
Published: 13 March 2020
View article titled, <em>EGFR</em> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma
Open the PDF for <em>EGFR</em> Amplification Induces Increased DNA Damage Response and Renders Selective Sensitivity to Talazoparib (PARP Inhibitor) in Glioblastoma in another window
Includes: Supplementary data
Journal Articles

Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer

Raju Kandimalla, Feng Gao, Takatoshi Matsuyama, Toshiaki Ishikawa, Hiroyuki Uetake, Naoki Takahashi, Yasuhide Yamada, Carlos Becerra, Scott Kopetz, Xin Wang, Ajay Goel
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (16): 3867–3877.
https://doi.org/10.1158/1078-0432.CCR-17-3236
Published: 14 August 2018
View article titled, Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer
Open the PDF for Genome-wide Discovery and Identification of a Novel miRNA Signature for Recurrence Prediction in Stage II and III Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer

Cynthia X. Ma, Ron Bose, Feng Gao, Rachel A. Freedman, Melinda L. Telli, Gretchen Kimmick, Eric Winer, Michael Naughton, Matthew P. Goetz, Christy Russell, Debu Tripathy, Melody Cobleigh, Andres Forero, Timothy J. Pluard, Carey Anders, Polly Ann Niravath, Shana Thomas, Jill Anderson, Caroline Bumb, Kimberly C. Banks, Richard B. Lanman, Richard Bryce, Alshad S. Lalani, John Pfeifer, Daniel F. Hayes, Mark Pegram, Kimberly Blackwell, Philippe L. Bedard, Hussam Al-Kateb, Matthew J.C. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5687–5695.
https://doi.org/10.1158/1078-0432.CCR-17-0900
Published: 01 October 2017
View article titled, Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer
Open the PDF for Neratinib Efficacy and Circulating Tumor DNA Detection of <em>HER2</em> Mutations in <em>HER2</em> Nonamplified Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer

Cynthia X. Ma, Feng Gao, Jingqin Luo, Donald W. Northfelt, Matthew Goetz, Andres Forero, Jeremy Hoog, Michael Naughton, Foluso Ademuyiwa, Rama Suresh, Karen S. Anderson, Julie Margenthaler, Rebecca Aft, Timothy Hobday, Timothy Moynihan, William Gillanders, Amy Cyr, Timothy J. Eberlein, Tina Hieken, Helen Krontiras, Zhanfang Guo, Michelle V. Lee, Nicholas C. Spies, Zachary L. Skidmore, Obi L. Griffith, Malachi Griffith, Shana Thomas, Caroline Bumb, Kiran Vij, Cynthia Huang Bartlett, Maria Koehler, Hussam Al-Kateb, Souzan Sanati, Matthew J. Ellis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (15): 4055–4065.
https://doi.org/10.1158/1078-0432.CCR-16-3206
Published: 01 August 2017
View article titled, NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer
Open the PDF for NeoPalAna: Neoadjuvant Palbociclib, a Cyclin-Dependent Kinase 4/6 Inhibitor, and Anastrozole for Clinical Stage 2 or 3 Estrogen Receptor–Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer

Cynthia X. Ma, Cesar Sanchez, Feng Gao, Robert Crowder, Michael Naughton, Timothy Pluard, Allison Creekmore, Zhanfang Guo, Jeremy Hoog, A. Craig Lockhart, Austin Doyle, Charles Erlichman, Matthew J. Ellis
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2016) 22 (11): 2650–2658.
https://doi.org/10.1158/1078-0432.CCR-15-2160
Published: 31 May 2016
View article titled, A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer
Open the PDF for A Phase I Study of the AKT Inhibitor MK-2206 in Combination with Hormonal Therapy in Postmenopausal Women with Estrogen Receptor–Positive Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer

Venkataswarup Tiriveedhi, Natalia Tucker, John Herndon, Lijin Li, Mark Sturmoski, Matthew Ellis, Cynthia Ma, Michael Naughton, A. Craig Lockhart, Feng Gao, Timothy Fleming, Peter Goedegebuure, Thalachallour Mohanakumar, William E. Gillanders
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (23): 5964–5975.
https://doi.org/10.1158/1078-0432.CCR-14-0059
Published: 30 November 2014
View article titled, Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer
Open the PDF for Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain

Xiaoyu Jiang, John A. Engelbach, Liya Yuan, Jeremy Cates, Feng Gao, Robert E. Drzymala, Dennis E. Hallahan, Keith M. Rich, Robert E. Schmidt, Joseph J.H. Ackerman, Joel R. Garbow
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2695–2702.
https://doi.org/10.1158/1078-0432.CCR-13-1941
Published: 14 May 2014
View article titled, Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain
Open the PDF for Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain in another window
Journal Articles

Aberrant Methylation of the X-Linked Ribosomal S6 Kinase RPS6KA6 (RSK4) in Endometrial Cancers

Summer B. Dewdney, BJ Rimel, Premal H. Thaker, Dominic M Thompson, Jr, Amy Schmidt, Phyllis Huettner, David G. Mutch, Feng Gao, Paul J. Goodfellow
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (8): 2120–2129.
https://doi.org/10.1158/1078-0432.CCR-10-2668
Published: 14 April 2011
View article titled, Aberrant Methylation of the X-Linked Ribosomal S6 Kinase <em>RPS6KA6 (RSK4)</em> in Endometrial Cancers
Open the PDF for Aberrant Methylation of the X-Linked Ribosomal S6 Kinase <em>RPS6KA6 (RSK4)</em> in Endometrial Cancers in another window
Journal Articles

A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing

Paula M. Fracasso, Howard Burris, III, Matthew A. Arquette, Ramaswamy Govindan, Feng Gao, Lisa P. Wright, Sherry A. Goodner, F. Anthony Greco, Suzanne F. Jones, Noel Willcut, Catherine Chodkiewicz, Amit Pathak, Gregory M. Springett, George R. Simon, Daniel M. Sullivan, Raphaël Marcelpoil, Shelley D. Mayfield, David Mauro, Christopher R. Garrett
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 986–993.
https://doi.org/10.1158/1078-0432.CCR-06-1542
Published: 08 February 2007
View article titled, A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing
Open the PDF for A Phase 1 Escalating Single-Dose and Weekly Fixed-Dose Study of Cetuximab: Pharmacokinetic and Pharmacodynamic Rationale for Dosing in another window
Journal Articles

A Prominent Low-pH Methotrexate Transport Activity in Human Solid Tumors: Contribution to the Preservation of Methotrexate Pharmacologic Activity in HeLa Cells Lacking the Reduced Folate Carrier

Rongbao Zhao, Feng Gao, Marie Hanscom, I. David Goldman
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (2): 718–727.
https://doi.org/10.1158/1078-0432.CCR-1066-03
Published: 03 February 2004
View article titled, A Prominent Low-pH Methotrexate Transport Activity in Human Solid Tumors: <subtitle>Contribution to the Preservation of Methotrexate Pharmacologic Activity in HeLa Cells Lacking the Reduced Folate Carrier</subtitle>
Open the PDF for A Prominent Low-pH Methotrexate Transport Activity in Human Solid Tumors: <subtitle>Contribution to the Preservation of Methotrexate Pharmacologic Activity in HeLa Cells Lacking the Reduced Folate Carrier</subtitle> in another window
Journal Articles

The Mechanism of Transport of the Multitargeted Antifolate (MTA) and Its Cross-resistance Pattern in Cells with Markedly Impaired Transport of Methotrexate

Rongbao Zhao, Solomon Babani, Feng Gao, Laibin Liu, I. David Goldman
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (9): 3687–3695.
Published: 01 September 2000
View article titled, The Mechanism of Transport of the Multitargeted Antifolate (MTA) and Its Cross-resistance Pattern in Cells with Markedly Impaired Transport of Methotrexate
Open the PDF for The Mechanism of Transport of the Multitargeted Antifolate (MTA) and Its Cross-resistance Pattern in Cells with Markedly Impaired Transport of Methotrexate in another window
Journal Articles

Sensitivity to 5,10-Dideazatetrahydrofolate Is Fully Conserved in a Murine Leukemia Cell Line Highly Resistant to Methotrexate Due to Impaired Transport Mediated by the Reduced Folate Carrier

Rongbao Zhao, Feng Gao, Solomon Babani, I. David Goldman
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (8): 3304–3311.
Published: 01 August 2000
View article titled, Sensitivity to 5,10-Dideazatetrahydrofolate Is Fully Conserved in a Murine Leukemia Cell Line Highly Resistant to Methotrexate Due to Impaired Transport Mediated by the Reduced Folate Carrier
Open the PDF for Sensitivity to 5,10-Dideazatetrahydrofolate Is Fully Conserved in a Murine Leukemia Cell Line Highly Resistant to Methotrexate Due to Impaired Transport Mediated by the Reduced Folate Carrier in another window